Zanubrutinib ya amince da USFDA don sake dawowa ko lymphoma follicular refractory

March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL)..

Matsayin Immunotherapy A cikin Jiyya na Lymphoma

If you're reading this, you or maybe one of your loved ones is on a journey that no one ever plans to take—the path of facing cancer. We understand that this road is filled with uncertainties, fears, and moments when it feel..

Mota-T Ciwon ƙwayar cuta, CAR T Therapy, T-Cell CAR, wakili na chimeric

Zurfafa Zurfi cikin CAR T Cell Therapy: Yaya Aiki yake?

Gano kimiyyar da ke bayan CAR T Cell therapy magani a Indiya! Bincika yadda wannan maganin juyin juya hali ke canza ƙwayoyin garkuwar jikin ku zuwa mayaƙan ciwon daji. Karanta blog ɗinmu yanzu don ƙarin koyo game da wannan maganin ban mamaki da yadda ..

T-Cell CAR, CAR far, immunotherapy, T cell far

Shin CAR T-Cell Ana Samun Farfawar Kwayoyin cuta A Indiya?

Shin kun taɓa tunanin ko akwai wata hanya mai ƙarfi don yaƙi da cutar kansa? Yanzu kawai ka yi tunanin idan wata rana ka sami haske na bege a cikin yaƙin da kake yi da kansa, maganin da ke amfani da ƙarfin garkuwar jikinka don kai hari.

Kwayar B-cell, Farashin DLBCL, POLARIX, Polatuzumab, polatuzumab vedotin

Polatuzumab vedotin-piiq ya amince da USFDA don a baya wanda ba a kula da shi ba babban lymphoma na B-cell, ba a kayyade ba, da kuma babban darajar B-cell lymphoma

Mayu 2023: Ga manya marasa lafiya tare da babban matakin B-cell lymphoma (HGBL), ba a kayyade ba (NOS), ko kuma yada manyan ƙwayoyin lymphoma B-cell (DLBCL) waɗanda ba a taɓa samun magani ba kuma waɗanda ke da Inde Prognostic Inde.

Karteyva, JW Therapeutics, linzoma, lymphoma follicular refractory, Nazarin RELIANCE, relmacabtagene autoleucel

JW Therapeutics Ya Sanar da Amincewar NMPA na Relmacabtagene Autoleucel Injection a cikin Marasa lafiya tare da Relapsed ko Refractory Follicular Lymphoma

SHANGHAI, CHINA, Oktoba 10, 2022 - JW Therapeutics (HKEX: 2126), wani kamfani mai zaman kansa kuma mai haɓaka fasahar kere kere wanda ke mai da hankali kan haɓakawa, masana'antu, da tallan samfuran rigakafin ƙwayoyin cuta, ya sanar da cewa Na...

ASTCT, CIBMTR, Babban lymphoma B-cell, Matiyu Frank, Miltenyi Biotec, Stanford University

Maƙasudin jiyya na novel ga marasa lafiya na lymphoma waɗanda suka koma bayan maganin CAR-T

Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..

Eli Lilly da kamfanin, FDA, Abinci da Drug Administration, Jaypicka, Mantle cell lymphoma, MCLs, pirtobrutinib

An ba da izini ga gaggawa ta FDA ga pirtobrutinib don sake dawowa ko ƙwayar lymphoma na mantle cell.

Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobr..

BeiGene Amurka, BRUKINSA, na kullum lymphocytic cutar sankarar bargo, SEQUOIA, ƙananan lymphocytic lymphoma

Zanubrutinib an amince da shi ta FDA don cutar sankarar lymphocytic na yau da kullum ko ƙananan lymphoma na lymphocytic

Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was used to assess effectiveness in CLL/SLL patients who had not recei..

Adcetris, brentuximab vedotin, Hodgkin lymphoma na gargajiya, Seagen Inc.

Brentuximab vedotin ya amince da FDA a hade tare da chemotherapy don marasa lafiya na yara tare da lymphoma na Hodgkin na gargajiya.

Nuwamba 2022: Haɗin doxorubicin, vincristine, etoposide, prednisone, da cyclophosphamide tare da brentuximab vedotin (Adcetris, Seagen, Inc.) Hukumar Abinci da Magunguna ta amince da ita don amfani a cikin yara.